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Objectives.We sought to assess the effect of advanced age on the
outcome of patients with an implantable cardioverter-defibrillator
(ICD).
Background. ICDs are effective in preventing sudden cardiac
death in susceptible patients, but their beneficial effect on survival
is attenuated by the high rate of nonsudden cardiac death in those
treated. Although advanced age is an important variable in
determining cardiovascular mortality, its impact on the outcome
of patients with an ICD has been inadequately studied.
Methods. We performed multivariate analysis of a data base
consisting of 769 consecutive patients with an ICD. Seventy-four
patients >275 years old at ICD implantation (Group 1) were
compared with the remaining 695 patients (Group 2).
Results. The two groups were similar in clinical presentation,
left ventricular function and gender distribution. The mean
follow-up time was 29 and 42 months, respectively, for patients in
Group 1 and Group 2. Actuarial survival at 4 years was 57% in
Group 1 versus 78% in Group 2 (p 5 0.0001). This difference was
primarily due to a higher rate of nonsudden cardiac death in
Group 1. On multivariate analysis, age >275 years, New York
Heart Association functional class III, left ventricular ejection
fraction <30% and appropriate shocks during follow-up were
independently associated with increased mortality (odds ratio
3.56, 1.8, 1.6 and 1.39, respectively).
Conclusions. Among patients with similar functional class and
ejection fraction, the mortality risk is increased threefold in those
>275 years old at the time of ICD implantation. Extrapolation of
results from younger patients is likely to overestimate ICD benefit
in the elderly.
(J Am Coll Cardiol 1997;29:556–60)
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In a society where health care cost is rapidly becoming a major
consideration in decision-making, it is important to know
precisely the effect of innovative and costly treatment modal-
ities on patient groups with factors thought to be at the
extremes of the spectrum in terms of risk stratification. Ad-
vanced age is such a factor and its relevance to clinical
decision-making is obvious given the increasingly aging popu-
lation in modern Western societies (1,2). Sudden cardiac death
(SCD) remains a significant health care problem with an
annual incidence of ;300,000 in the United States (3). Au-
thorities (4) appear to agree that the implantable cardioverter-
defibrillator (ICD) reduces the incidence of SCD in high risk
patients. This consensus, along with the ease of ICD implan-
tation with minimal complications, technologic advances in
ICDs and physicians’ tendency to overtreat rather than under-
treat patients at risk for SCD, has led to an exponential
increase in rates of ICD implantation. However, some inves-
tigators (5–9) have questioned whether reducing the risk of
SCD leads to prolongation of life, as many patients at in-
creased risk of SCD also have advanced heart disease and
significant comorbid illnesses. Although this issue may be
particularly relevant in elderly patients, little has been pub-
lished (10) on the effect of age on the benefit derived from
ICDs. The present study is an attempt to assess this effect.
Methods
Seven hundred sixty-nine consecutive patients who under-
went ICD implantation between September 1983 and Septem-
ber 1995 were included. Of these, 74 patients (Group 1) were
$75 years old at the time of implantation; the remaining 695
patients form Group 2. The end point of follow-up was March
31, 1996 (which assured a minimal follow-up period of 6
months) or death, if it occurred before that date. For patients
lost to follow-up, the end point was the last follow-up contact.
The clinical characteristics of the two patient groups are
summarized in Table 1. The majority of patients (90% in
Group 1) had coronary artery disease; fewer patients had
nonischemic cardiomyopathy, valvular heart disease or other
underlying conditions. Most patients had an ICD implanted
because of aborted SCD, spontaneous ventricular tachycardia
(VT) or syncope with inducible VT in the setting of left
ventricular (LV) dysfunction. Before ICD implantation, the
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nature and severity of the underlying heart disease were
assessed with studies that included, when indicated, cardiac
catheterization, echocardiography and nuclear imaging stud-
ies. Implantation techniques evolved from thoracotomy ap-
proaches used initially to the current transvenous systems.
The patients were followed up at 2- to 3-month intervals
clinically and with device interrogation. To minimize the
frequency of device discharge, antiarrhythmic medications
were used as needed to control supraventricular or ventricular
arrhythmias.
Whenever a device discharge occurred in an unmonitored
situation, the patient was interviewed in an attempt to assess
the appropriateness of the discharge. The discharge was con-
sidered appropriate if there was electrocardiographic docu-
mentation of arrhythmia at the time of discharge or if the
shock had been preceded by syncope or symptoms consistent
with cerebral hypoperfusion that resolved immediately after-
ward. Shocks that were not preceded by symptoms, that
occurred in association with palpitation but not dizziness or
that occurred during intense physical activity were not consid-
ered appropriate unless a qualifying arrhythmia was docu-
mented by an event monitor, stored electrogram or similar
means. Finally, shocks attributed to device-induced proar-
rhythmia (i.e., VT acceleration or degeneration into ventricu-
lar fibrillation [VF]) were also not considered appropriate.
Deaths were classified as cardiac, sudden cardiac, nonsud-
den cardiac or noncardiac on the basis of data derived from
postmortem device interrogation, history obtained from family
members or witnesses, hospital records and involved physi-
cians. Sudden cardiac death (SCD) was defined as death that
occurred unexpectedly, within 1 h of symptom onset, or that
was unwitnessed, as during sleep, in a patient who had been
witnessed to be well just before death. Cardiac death (CD) was
defined as any death due to cardiac causes and included both
SCD and nonsudden CD. Noncardiac death included all deaths
not classified as CD (11).
Data were expressed as mean value 6 SD or as a percent.
Comparisons were made by using the Student t test, the
chi-square test or the Fisher exact test as appropriate. Survival
curves were presented by using the Kaplan-Meier method. The
log-rank method was used for statistical analysis of differences
between survival curves. Independent predictors of mortality
and odds ratios were determined by using the Cox proportional
hazards model. The SAS system (SAS Institute) was used for
statistical analysis. Differences were considered statistically
significant at p , 0.05.
Results
The mean age at ICD implantation was 77.2 years (range 75
to 84) in Group 1 and 60.8 years (range 15 to 74) in Group 2.
The mean left ventricular ejection fraction (LVEF) and the
percentage of patients with LVEF,30% were almost identical
in the two groups. Most patients in either group were in New
York Heart Association (NYHA) functional class I or II.
There were no patients in NYHA class IV at the time of
implantation and there were no significant differences in the
presenting arrhythmia in the two groups. The percentage of
patients undergoing concomitant coronary bypass surgery or
cryoablation was similar in the two groups as was the mode of
implantation (Table 1).
Survival. The mean follow-up interval was 29.1 6 23.0
months (range 1 day to 115 months) for Group 1 patients and
42.2 6 31.7 months (range 0 day to 151 months) for Group 2
patients. Eleven patients were lost to follow-up (1 [1.4%] from
Group 1 and 10 [1.4%] from Group 2). These patients were
censored at the point they were lost to follow-up. Perioperative
mortality was very low: One elderly patient (1.4%) and five
younger patients (0.7%) died within 1 month of ICD implan-
tation. Survival data are shown in Table 2. At 2 and 4 years of
follow-up, actuarial survival was 80% and 57%, respectively, in
Group 1 versus 90% and 78% in Group 2 (p 5 0.0001).
Actuarial freedom from SCD in the two groups was 100% and
98%, respectively, at 2 years and 100% and 97% at 4 years (p5
NS). Actuarial freedom from cardiac death was 86% and 76%
at 2 and 4 years, respectively, in Group 1 versus 93% and 87%
in Group 2 in the same time period (p , 0.001). Percentage
free from noncardiac death at 2 and 4 years was 93% and 75%,
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CASS 5 Coronary Artery Surgery Study
CD 5 cardiac death
ICD 5 implantable cardioverter-defibrillator
LV 5 left ventricular
LVEF 5 left ventricular ejection fraction
NYHA5 New York Heart Association
SCD 5 sudden cardiac death
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
Table 1. Clinical Characteristics
Group 1
($75 years old)
(n 5 74)
Group 2
(,75 years old)
(n 5 695)
p
Value
Age (yr) 77.2 6 2.5 60.8 6 10.1 0.0001
Female 28.4% 18.8% NS
CAD 90.4% 78.5% 0.05
LVEF 0.32 0.33 NS
LVEF #0.30 41.7% 43.8% NS
Presenting arrhythmia
Polymorphic VT/VF 37% 37.5% NS
Monomorphic VT 42.5% 33.1% NS
Others* 21.5% 29.4% NS
Epicardial implant 42.7% 66.4% NS
Concomitant bypass surgery 13.3% 20.1% NS
*Syncope or nonsustained ventricular tachycardia with inducible, sustained
ventricular tachycardia during electrophysiologic study. Data are expressed as
mean value, mean value 6 SD or percent of patient group. CAD 5 coronary
artery disease; LVEF 5 left ventricular ejection fraction; VF 5 ventricular
fibrillation; VT 5 ventricular tachycardia.
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respectively, in Group 1 and 97% and 91% in Group 2 (p ,
0.01). Kaplan-Meier survival curves are depicted in Figure 1.
Device use. At 4 years of follow-up actuarial freedom from
appropriate shock, as defined previously, was 58% in the
elderly and 57% in the younger patients (p 5 NS). Kaplan-
Meier curves of appropriate shocks delivered by the device are
shown in Figure 2. During the entire period of follow-up, 27
elderly patients (36.5%) received appropriate shocks, 8
(10.8%) received indeterminate shocks and 39 (52.7%) re-
ceived no shocks. Among the younger patients, 261 (37.6%),
127 (18.3%) and 307 (44.2%), respectively, received appropri-
ate, indeterminate and no shocks. The mean time from ICD
implantation to first appropriate shock was 10.2 6 14.5 and
13.3 6 18.1 months (p 5 NS) and the mean time from first
appropriate shock to death or last follow-up was 22.4 6 19.0
and 37.7 6 30.2 months, respectively, in Group 1 and Group 2
(p , 0.001) (Table 3).
Predictors of mortality. The results of a multivariate anal-
ysis to determine which factors, if any, were independently
associated with increased mortality are shown in Table 4. Age
$75 years at implantation was the most powerful predictor of
an adverse outcome (odds ratio 3.56, confidence interval 2.28
to 5.54). Other factors independently associated with mortality
were ejection fraction ,30% at implantation, NYHA class III
and appropriate shocks during follow-up. Factors considered
in this analysis, but not found to be of independent prognostic
significance, included clinical presentation, type of heart dis-
ease, gender, history and location of myocardial infarction.
Discussion
In this large single-center experience the ICD conferred
near elimination of SCD risk in the elderly, to the same extent
as in younger patients. However, the elderly had a significantly
higher total mortality rate. Although the higher death rate in
this age group would seem expected and obvious, we found
that it was primarily due to an increase in nonsudden cardiac
death. In fact, the variable with the highest odds ratio for total
as well as cardiac mortality in our ICD patients, as assessed by
a multivariate analysis model, was age $75 years at implanta-
tion.
Some investigators (6,8) have questioned the benefit of the
ICD in prolonging life in any patient age group, an issue that
may be particularly relevant in the elderly at risk for SCD.
Several randomized studies are underway to assess the efficacy
of ICD therapy versus antiarrhythmic medications in prolong-
ing life, but it is unlikely that these studies will have sufficient
numbers of patients to address the use of ICDs in the elderly.
Although our study is retrospective, it is the first large study
Table 2. Survival Data
Group 1
($75 years old)
Group 2
(,75 years old)
p
Value1 Year 2 Years 3 Years 4 Years 1 Year 2 Years 3 Years 4 Years
Freedom from SCD 100% 100% 100% 100% 98% 98% 97% 97% NS
Freedom from CD 94% 86% 76% 76% 96% 93% 91% 87% ,0.001
Freedom from NCD 93% 93% 87% 75% 99% 97% 94% 91% ,0.01
Actuarial survival 87% 80% 66% 57% 94% 90% 84% 78% 0.0001
CD 5 cardiac death; NCD 5 noncardiac death; SCD 5 sudden cardiac death.
Figure 1. Kaplan-Meier curves showing actuarial survival and freedom
from sudden cardiac death (SD) and cardiac death (CD) in Group 1
(patients $75 years old) and Group 2 (patients ,75 years old).
Figure 2. Kaplan-Meier curves comparing actuarial freedom from
appropriate shock in Group 1 (patients $75 years old) and Group 2
(patients ,75 years old).
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that has examined the pattern of ICD usage and outcome in
patients.75 years old. We arbitrarily chose 75 years as the age
cutoff point in an effort to identify a variable that would be
useful in clinical decision-making. Currently 13% of the pop-
ulation in the U.S. are.65 years old and 3% are.80 years old
(1). Among our ICD patients, ;10% are .75 years old. The
average life expectancy for the general population in this age
group is 10.7 years (12). An appropriate intervention in this
age group could therefore have a significant impact on survival.
Age and cardiovascular mortality. Mortality due to cardio-
vascular disorders even in the absence of arrhythmias is known
to be adversely influenced by advanced age. For example, the
21-day mortality rate in the control group of the Gruppo
Italiano per lo Studio della Streptochinasi nell’Infarto Mio-
cardico (GISSI)-1 trial (13) rose from 7.7% in patients ,65
years old to 33.1% in those.75 years old. Similarly, the 1-year
mortality rate after hospital discharge was 6% in patients ,55
years old and 33% in patients $75 years old in the Worcester
Heart Attack Study (14). Among patients undergoing coronary
artery bypass (CABG) surgery, perioperative mortality was
1.9% in those ,65 years old versus 9.5% in patients 75 to 84
years old (15). Data from the Coronary Artery Surgery Study
(CASS) registry show a 91% 5-year survival rate in patients
,65 years old versus 70% in patients .75 years old (16). To
some extent this increased mortality in the elderly is attribut-
able to poorer baseline values for variables known to affect
survival in these settings. However, another important factor is
physician reluctance to implement appropriate therapeutic
strategies that are associated with more frequent complications
in the elderly. In fact, appropriately aggressive interventions
such as thrombolytic therapy, for example, may result in a
greater mortality reduction in the elderly than in younger, less
high risk patients (1). Whether an intervention such as the ICD
would similarly benefit elderly patients needs to be deter-
mined.
Assessment of ICD benefit in the elderly. In the absence of
randomized prospective data two methods have been used to
try to assess ICD benefit in the elderly. The first compares
historical control subjects with ICD patients (17–19). However,
identification of historical control subjects is problematic in
studies that extend over a period of time during which signif-
icant changes in both anti-ischemic and antiarrhythmic man-
agement have occurred. The second method involves the
assumption that the time of the first appropriate shock would
have been the time of death had the ICD not been implanted
(5,20–23). Criticism of this method is based on the fact that
some of the appropriate shocks may have been given for
nonsustained events by committed devices, for hemodynami-
cally tolerated events or for fast VT or VF precipitated by
attempts by the device to pace-terminate slower VT (6–8).
Because of these methodologic limitations, along with prob-
lems often associated with accurately determining the mode of
death, it has been suggested (11) that total mortality should be
considered the primary end point in survival studies of patients
with an ICD.
The present study highlights the difficulties associated with
ICD use in the elderly. Our data suggest that elderly and
younger patients at risk for SCD have a similar frequency of
arrhythmic events. The almost total absence of SCD death in
both groups implies that the ICD confers its stated benefit of
effectively treating arrhythmias in these patients. However, this
benefit appears to be significantly attenuated in the elderly
because of a threefold increase in overall mortality in this
group. Our findings, therefore, caution against extrapolation to
the elderly of ICD outcome studies performed predominantly
in younger patients. A true assessment of the ICD benefit in
the elderly can be obtained only by a prospective randomized
trial. Because of the higher total mortality among the elderly,
the importance of such a trial is obviously greater in this group
than in younger patients. In the absence of such a trial, the
challenge to the implanting physician will be to identify among
the elderly those patients at relatively low risk for nonsudden
cardiac death, who are likely to derive the most benefit from
the device.
Study limitations. The retrospective design of this report is
its major limitation. Selection bias may have been involved
during decision-making for ICD implantation in the elderly,
particularly during the period before nonthoracotomy devices
became available. We did not attempt to introduce concomi-
tant pharmacologic management (including antiarrhythmic
and anti-ischemic or heart failure treatment) as a variable in
our study. Although this is an important omission, over the
follow-up period significant changes occurred in what was
considered state of the art treatment as a result of the Cardiac
Arrhythmia Suppression Trial (CAST), introduction of
angiotensin-converting enzyme inhibitors and recognition of
the role of beta-blockers. The changes made over time in each
Table 3. Device Utilization
Group 1
($75 years old)
Group 2
(,75 years old)
p
Value
Shock
Appropriate 36.5% 37.6% NS
Indeterminate 10.8% 18.3% NS
No shock 52.7% 44.2% NS
Mean time (mo)
From implantation to 1st
appropriate shock
10.2 6 14.5 13.3 6 18.1 NS
From 1st appropriate shock to
last f/u or death
22.4 6 19.0 37.7 6 30.2 ,0.001
Data are expressed as mean value 6 SD or percent of patient group. f/u 5
follow-up.
Table 4. Multivariate Predictors of Mortality During Follow-Up
Odds Ratio Confidence Interval
Age $75 years 3.56 2.28–5.54
NYHA class III 1.8 1.14–2.85
LVEF ,30% 1.6 1.18–2.17
Appropriate shock 1.39 1.04–1.87
LVEF 5 left ventricular ejection fraction, NYHA class 5 New York Heart
Association functional class.
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individual patient’s regimen made such a comparison impos-
sible.
Conclusions. The ICD can be placed with minimal risk in
elderly patients and is as effective in preventing sudden cardiac
death in this group as in younger patients. However, among
patients with similar functional class and ejection fraction, the
risk of nonsudden cardiac death is increased threefold in
patients $75 years old at ICD implantation. Extrapolation of
results from younger patients is likely to overestimate the
benefit of ICD implantation in the elderly. Conversely, inclu-
sion of a large number of elderly patients in such studies is
likely to result in underestimation of the potential benefits of
ICD implantation in younger patients.
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